The newly formed medtech alliance comprised of Kinetic Concepts, LifeCell and Systagenix posted collective figures that put the group in the red for Q4, a recent SEC filing shows.
Regenerative Medicine
Shire ditches troubled Dermagraft skin substitute
FDA walks back Regenesis contraindication
Arizona medical device maker Regenesis Biomedical won new labeling for its Provant Therapy system, removing a contraindication discouraging doctors from using the system on patients with metallic implants in the area of treatment.
The company’s Provant system uses electromagnetic energy to help manage pain and edema in soft tissues following surgery, working by spurring the body’s own pain-relief mechanisms and regulating inflammation responses.
Bioheart launches clinical trial for stem cell vision loss therapy
Cytomedix raises $3M for regenerative therapies
Soft Tissue Regeneration raises $4.7M for biodegradable scaffold
Orthopedics maker Soft Tissue Regeneration is closing in on a $5 million funding round, with $4.7 million raised so far.
The New Haven, Conn.-based company is raising funds through sales of equity, options, warrants and other securities, with 14 unnamed investors listed so far in regulatory filings.
UCSF and Sitoa Global sign global deal for brain stem cell injection technology
China-based Sitoa Global is making some big moves after landing an exclusive licensing contract with UC San Francisco, according to a company announcement.
Sitoa signed an exclusive letter of intent for UCSF’s "medical stereotactic device," designed to streamline the therapeutic delivery of stem cells into the brain.
BioCardia touts positive outcomes for Helical stem cell therapy system
California-based BioCardia Inc. announced this week positive findings from a clinical trial of its Helical Infusion Catheter System for injecting stem cells into the heart in treatment of chronic ischemic cardiomyopathy.
Kinetic Concepts slips in Q3, losses widen for Systagenix, LifeCell triad
Sales took a minor hit for Kinetic Concepts during its 3rd quarter 2013, reporting as part of the Centaur Guernsey companies which now includes both LifeCell and Systagenix.
World’s 1st regenerated trachea recipient faring well at 5 years
Harvard Bioscience ditches IPO in favor of a spin-out
Harvard Bioscience’s (NSDQ:HBIO) regenerative therapies business will begin operating as an independent, publicly traded company at the start of next month, ditching original plans to launch an initial public offering.